Sakai, Japan

Kazunobu Tachibana

This inventor holds 3 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Shionogi Company Limited, Chugai Seiyaku Kabushiki Kaisha, Tadamitsu Kishimoto. Active years: 2006-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kazunobu Tachibana. Retrieved from https://idiyas.com/inventor/kazunobu-tachibana

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 3 

% Patents Active = 33.3

 

Average Co-Inventor Count = 4.8

ph-index = 2

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2006-2012

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Kazunobu Tachibana: Innovator in Therapeutic Agents

Introduction

Kazunobu Tachibana is a prominent inventor based in Sakai, Japan. He has made significant contributions to the field of therapeutic agents, particularly in the context of vascularization and HIV-1 infection. With a total of 3 patents, his work has the potential to impact various medical treatments.

Latest Patents

One of his latest patents focuses on inhibiting vascularization using antibodies to CXCR4 and SDF-1. This invention provides a therapeutic agent for inhibiting neovascularization, which is crucial for treating solid cancers and diseases caused by abnormal vascularization. The therapeutic agent comprises a substance that potentiates the action of CXCR4, based on findings that vascularization is suppressed in CXCR4 knockout mice. This opens up possibilities for preparing therapeutic agents that can suppress vascularization and repair tissues.

Another significant patent involves a mouse CXC chemokine receptor. This invention pertains to a DNA encoding a polypeptide that can bind to murine PBSF/SDF-1. It also includes a method for screening an AIDS onset inhibitor or an HIV-1 infection inhibitor. This novel murine CXC chemokine receptor gene is valuable for studies related to therapeutic agents for AIDS and understanding the functional mechanisms of HIV-1 infection.

Career Highlights

Kazunobu Tachibana has worked with Shionogi & Company Limited, where he has furthered his research and development in therapeutic agents. His career reflects a commitment to advancing medical science through innovative inventions.

Collaborations

He has collaborated with notable individuals in the field, including Tadamitsu Kishimoto and Takashi Nagasawa. These collaborations have likely contributed to the depth and impact of his research.

Conclusion

Kazunobu Tachibana's work in developing therapeutic agents showcases his innovative spirit and dedication to improving medical treatments. His patents hold promise for significant advancements in the treatment of various diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…